...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pathology oncology research: POR >Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer
【24h】

Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer

机译：S-1和奥沙利铂（SOX）联合化疗作为老年晚期胃癌患者的一线治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with S-1 and oxaliplatin (SOX) as first-line treatment in elderly patients with advanced gastric cancer. One hundred and twenty-nine patients with recurrent or metastatic gastric adenocarcinoma were treated with SOX; S-1 (40–60?mg depending on patient’s body surface area) was given orally, twice daily on days 1 to 14 followed by a 7-day rest period, 130?mg/m2 oxaliplatin was given as an intravenous infusion over 2-hours on day one. The cycle was repeated every three weeks. All of the patients were older than 65?years. Among 129 patients enrolled, nine patients could not be evaluated for responses because of the absence of any measurable lesions or early discontinuation of therapy. Assessment of the response of 120 patients was made. The overall objective response rate was 54.2?% (95?%CI, 45.3–63.1?%), with three complete responses and 62 partial responses. The disease control rate was 80.8?% (95?%CI, 73.8–87.8?%). The median follow-up period was 23?months (range, 5–42 months). The median time to progression was 6.9?months (95?%CI, 5.5–8.3?months) and the median overall survival was 12.8?months (95?%CI, 11.4–14.2?months). The one-year survival rate was 57.5?% (95?%CI, 48.7–66.3?%). In 129 patients assessed safety, grade 3 and 4 toxicities included leucopenia (20.9?%), neutropenia (24.0?%), anemia (10.9?%), thrombocytopenia (10.1?%), anorexia (3.1?%), peripheral neurotoxicity (15.5?%), and fatigue (12.4?%). No treatment-related deaths occurred. Combination chemotherapy with SOX offers an effective, safe and well-tolerated regimen for elderly patients with advanced gastric cancer.
机译：这项研究是一项回顾性分析，评估了S-1和奥沙利铂（SOX）联合化疗作为老年晚期胃癌患者一线治疗的疗效和毒性。 SOX治疗129例复发或转移性胃腺癌患者。口服S-1（40–60？mg，取决于患者的身体表面积），在第1至14天每天两次，然后休息7天，奥沙利铂为130？mg / m 2 在第一天的2小时内以静脉输注的方式给予。该周期每三周重复一次。所有患者年龄均在65岁以上。在入组的129例患者中，有9例因缺乏可测量的病变或早期停止治疗而无法评估反应。评估了120例患者的反应。总体客观缓解率为54.2％（95％CI，45.3-63.1％），其中三个完全缓解和62个部分缓解。疾病控制率为80.8％（95％CI，73.8-87.8％）。中位随访期为23个月（5-42个月）。中位进展时间为6.9个月（95 %% CI，5.5-8.3个月），中位总生存期为12.8个月（95 %% CI，11.4-14.2个月）。一年生存率为57.5％（95％CI，48.7-66.3％）。在经评估安全性的129位患者中，三级和四级毒性包括白细胞减少症（20.9％），中性粒细胞减少症（24.0％），贫血（10.9 %%），血小板减少症（10.1 %%），厌食症（3.1 %%），周围神经毒性（ 15.5％）和疲劳（12.4％）。没有发生与治疗有关的死亡。 SOX联合化疗为老年晚期胃癌患者提供了一种有效，安全且耐受良好的方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号